$556.3M in CY2024 Part D spend1.3M claims · 324K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Umeclidinium used for?
ANORO ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Is there a generic for Umeclidinium?
No. Umeclidinium is brand-only with no generic equivalents currently in market.
How much does my plan pay for Umeclidinium?
Across 329 Part D plans, Umeclidinium averages $10.78/unit (NADAC). Lowest available: $10.26/unit. Highest in distribution: $11.31/unit.
Is Umeclidinium on the FDA shortage list?
No. Umeclidinium is not currently on the FDA Drug Shortage Database.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (1 approvals on file) · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.